OCULAR THERAPEUTIX, INC

OCUL

OCULAR THERAPEUTIX, INC

OCUL

Insider Sentiment (TTM):

Last Purchase:2026-02-20Last Sale:2026-06-03Shares Purchased (TTM):60,229Shares Sold (TTM):321,115

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:198,231,265Shares Outstanding:224,099,410Institutional Ownership Pct.:88.46%

Earnings Market Reaction:

Filing Date:2026-08-03Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	599	667	737	345	391	350	392	427	460	483	196	111
Accounts Receivable Net Current	30	24	31	31	30	25	32	30	30	27	26	24
Inventory Net	4	4	4	3	3	3	3	2	3	3	2	2
Restricted Cash Current	-	-	-	-	-	-	-	-	-	0	0	-
Restricted Cash And Cash Equivalents At Carrying V…	-	-	-	-	-	-	-	-	-	-	0	-
Prepaid Expense And Other Assets Current	12	11	11	8	9	10	13	13	6	8	8	5
Assets Current	644	706	782	387	433	388	441	473	499	520	232	141
Property Plant And Equipment Net	19	18	20	17	10	11	9	10	11	11	12	12
Restricted Cash And Cash Equivalents Noncurrent	-	-	-	-	-	-	-	-	-	-	2	2
Restricted Cash Noncurrent	2	2	2	2	2	2	2	2	2	2	2	-
Operating Lease Right Of Use Asset	6	6	5	5	6	6	6	6	6	6	6	7
Assets	671	733	808	411	451	406	458	490	517	539	252	162
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	7	8	4	6	6	5	4	4	4	6	4	4
Accrued Liabilities Current	39	36	44	40	34	31	35	30	24	16	29	29
Contract With Customer Liability Current	-	-	-	-	-	0	0	0	0	0	0	0
Operating Lease Liability Current	3	3	3	3	3	2	2	2	2	2	2	2
Liabilities Current	49	48	51	49	43	38	41	36	30	24	35	35
Other Liabilities Noncurr…
Operating Lease Liability Noncurrent	3	4	3	4	4	5	5	6	6	6	7	7
Derivative Liabilities Noncurrent	11	12	14	15	14	14	13	14	22	20	30	24
Contract With Customer Liability Noncurrent	14	14	14	14	14	14	14	14	14	14	14	14
Long Term Notes Payable	73	72	71	71	70	69	69	68	67	66	66	65
Other Liabilities Noncurrent	1	1	1	0	0	0	0	0	0	0	0	0
Convertible Debt Noncurrent	-	-	-	-	-	-	-	-	-	-	9	9
Liabilities	151	151	154	153	145	140	143	138	139	131	161	155
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	1,844	1,827	1,811	1,351	1,329	1,221	1,206	1,195	1,184	1,170	789	676
Retained Earnings Accumulated Deficit	-1,324	-1,246	-1,157	-1,092	-1,023	-955	-891	-843	-806	-762	-698	-668
Stockholders Equity	520	582	654	258	306	266	315	352	378	408	91	8
Liabilities And Stockholders Equity	671	733	808	411	451	406	458	490	517	539	252	162
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	400	400	400	400	400	400	400	400	400	200	200	200
Common Stock Shares Issued	220	219	216	175	173	159	158	157	156	155	115	79
Shares Outstanding	220	219	216	175	173	159	158	157	156	155	115	79

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-7.21%	1.34%	-12.41%	-	-	-	-	-	-	-	-	-
2025	3.62%	19.28%	57.96%	1.75%	4.42%	-4.25%	11.47%	15.23%	-5.78%	0.34%	-15.26%	6.51%
2024	-3.88%	15.35%	42.16%	5.38%	3.70%	33.09%	-3.02%	-11.69%	-22.38%	27.93%	30.13%	23.21%
2023	-	-	-	-11.24%	-27.98%	-44.50%	-5.63%	57.04%	64.08%	-13.26%	-36.59%	-41.42%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	13.11	14.81	15.39	7.85	10.09	10.22	10.66	13.01	16.64	21.39	6.66	4.03
Quick Ratio	12.79	14.49	15.11	7.62	9.82	9.89	10.26	12.58	16.35	20.97	6.37	3.83
Working Capital	595.25M	658.31M	731.32M	337.69M	390.44M	349.77M	399.63M	436.65M	468.61M	495.53M	197.34M	106.19M
Leverage & Debt
Debt to Equity	0.29	0.26	0.23	0.59	0.48	0.53	0.45	0.39	0.37	0.32	1.77	19.68
Interest Coverage TTM	-27.53	-25.75	-22.82	-20.72	-18.50	-16.31	-12.65	-9.66	-7.72	-6.71	-7.27	-9.05
Debt Ratio	0.23	0.21	0.19	0.37	0.32	0.34	0.31	0.28	0.27	0.24	0.64	0.95
Efficiency & Turnover
Asset Turnover TTM	0.09	0.09	0.08	0.12	0.12	0.13	0.18	0.19	0.19	0.18	0.29	0.36
Days Sales Outstanding TTM	212.72	173.84	221.45	199.57	195.32	158.39	167.73	159.87	171.88	145.38	148.34	137.20
Receivables Turnover TTM	1.72	2.10	1.65	1.83	1.87	2.30	2.18	2.28	2.12	2.51	2.46	2.66
Per Share Metrics
Diluted EPS TTM	-1.34	-1.30	-1.42	-1.36	-1.26	-1.14	-1.22	-1.04	-0.83	-0.87	-0.94	-0.79
Free Cash Flow Per Share TTM	-1.13	-1.08	-1.16	-1.08	-1.04	-0.88	-0.86	-0.71	-0.55	-0.66	-0.96	-0.91
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	87.11%	87.24%	87.35%	88.87%	89.42%	90.68%	91.17%	90.59%	90.84%	90.99%	90.96%	91.50%
Operating Profit Margin TTM	-603.04%	-575.43%	-519.75%	-449.65%	-402.60%	-342.15%	-269.57%	-229.90%	-187.35%	-152.82%	-140.96%	-141.54%
Net Profit Margin TTM	-579.10%	-558.24%	-511.90%	-447.57%	-382.51%	-323.09%	-303.67%	-283.74%	-226.46%	-192.61%	-138.14%	-116.18%
Growth Metrics
Net Revenue Growth (1Y)	-8.14%	-12.76%	-18.47%	-9.21%	-7.26%	-0.33%	9.03%	6.45%	11.90%	15.79%	13.49%	16.07%
Net Income Growth (1Y)	39.08%	50.74%	37.43%	43.21%	56.65%	67.19%	139.68%	159.98%	52.50%	29.78%	13.65%	12.99%
EPS Growth (1Y)	6.71%	13.95%	16.16%	30.03%	50.51%	30.30%	20.89%	23.57%	-28.22%	-23.93%	9.45%	9.58%
Valuation Metrics
P/E TTM	-7.33	-6.53	-8.55	-8.61	-7.39	-6.44	-6.98	-8.33	-8.20	-10.42	-4.41	-3.72
P/B TTM	4.25	3.26	3.47	8.33	5.24	4.67	4.29	4.13	3.00	2.94	3.91	31.74
P/S TTM	42.44	36.48	43.75	38.54	28.27	20.82	21.21	23.65	18.56	20.08	6.09	4.32
Market Cap	2.21B	1.90B	2.27B	2.15B	1.60B	1.24B	1.35B	1.45B	1.13B	1.20B	356.03M	249.23M
Enterprise Value	1.68B	1.30B	1.61B	1.87B	1.28B	959.59M	1.03B	1.09B	740.07M	783.20M	233.38M	210.81M
Calculated Values
Free Cash Flow TTM	-255.10M	-240.94M	-216.89M	-199.44M	-179.37M	-148.43M	-135.97M	-119.25M	-90.59M	-87.11M	-76.32M	-72.52M
Net Debt	-527.46M	-596.25M	-667.34M	-275.77M	-322.84M	-282.09M	-325.21M	-361.02M	-394.17M	-418.20M	-122.65M	-38.43M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-03Sale

Owner: Waheed, Nadia

Title: Chief Medical Officer

Shares: 14,828

Price/Share: $8.27

Value: $122,627.56

Shares Owned: 300,079

Relationship: Officer

Ownership: Direct

2026-05-26Sale

Owner: Kaiser, Peter

Title: Chief Development Officer

Shares: 2,967

Price/Share: $8.20

Value: $24,329.40

Shares Owned: 266,141

Relationship: Officer

Ownership: Direct

2026-05-26Sale

Owner: Dugel, Pravin

Title: See Remarks

Shares: 21,156

Price/Share: $8.20

Value: $173,479.20

Shares Owned: 2,597,170

Relationship: Director,Officer

Ownership: Direct

2026-05-26Sale

Owner: Nayak, Sanjay

Title: Chief Strategy Officer

Shares: 1,858

Price/Share: $8.20

Value: $15,235.60

Shares Owned: 328,795

Relationship: Officer

Ownership: Direct

2026-05-26Sale

Owner: Heier, Jeffrey S.

Title: Chief Scientific Officer

Shares: 3,018

Price/Share: $8.20

Value: $24,747.60

Shares Owned: 320,350

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-03	Waheed, Nadia	Officer	Chief Medical Officer	Direct	Sale	14,828	8.27	$122,627.56	300,079	4
2026-05-26	Kaiser, Peter	Officer	Chief Development Officer	Direct	Sale	2,967	8.20	$24,329.40	266,141	4
2026-05-26	Dugel, Pravin	Director,Officer	See Remarks	Direct	Sale	21,156	8.20	$173,479.20	2,597,170	4
2026-05-26	Nayak, Sanjay	Officer	Chief Strategy Officer	Direct	Sale	1,858	8.20	$15,235.60	328,795	4
2026-05-26	Heier, Jeffrey S.	Officer	Chief Scientific Officer	Direct	Sale	3,018	8.20	$24,747.60	320,350	4
2026-02-23	Kaiser, Peter	Officer	Chief Development Officer	Direct	Sale	2,810	8.28	$23,266.80	269,108	4
2026-02-23	Heier, Jeffrey S.	Officer	Chief Scientific Officer	Direct	Sale	3,057	8.28	$25,311.96	323,368	4
2026-02-23	Dugel, Pravin	Director,Officer	See Remarks	Direct	Sale	20,056	8.28	$166,063.68	3,013,022	4
2026-02-23	Nayak, Sanjay	Officer	Chief Strategy Officer	Direct	Sale	1,759	8.28	$14,564.52	330,653	4
2026-02-20	Waheed, Nadia	Officer	Chief Medical Officer	Direct	Sale	3,510	7.74	$27,167.40	314,907	4
2026-02-20	Lindstrom, Richard L Md	Director	-	Direct	Purchase	60,229	7.66	$461,354.14	246,933	4
2026-02-12	Nayak, Sanjay	Officer	Chief Strategy Officer	Direct	Sale	10,348	9.04	$93,545.92	332,412	4
2026-02-12	Notman, Donald	Officer	Chief Operating Officer	Direct	Sale	11,446	9.04	$103,471.84	366,356	4
2026-02-12	Waheed, Nadia	Officer	Chief Medical Officer	Direct	Sale	7,863	9.04	$71,081.52	318,417	4
2026-02-12	Dugel, Pravin	Director,Officer	See Remarks	Direct	Sale	124,882	9.04	$1,128,933.28	3,033,078	4
2026-02-02	Notman, Donald	Officer	Chief Operating Officer	Direct	Sale	5,455	9.14	$49,858.70	383,837	4
2025-11-24	Heier, Jeffrey S.	Officer	Chief Scientific Officer	Direct	Sale	3,469	12.04	$41,766.76	245,940	4
2025-11-24	Kaiser, Peter	Officer	Chief Development Officer	Direct	Sale	3,007	12.02	$36,144.14	191,433	4
2025-11-24	Dugel, Pravin	Director,Officer	See Remarks	Direct	Sale	19,530	12.04	$235,141.20	3,157,960	4
2025-11-24	Nayak, Sanjay	Officer	Chief Strategy Officer	Direct	Sale	1,878	12.04	$22,611.12	277,860	4
2025-11-05	Saroj, Namrata	Officer	Chief Business Officer	Direct	Sale	25,865	10.74	$277,790.10	174,135	4
2025-10-08	Anderman, Todd	Officer	Chief Legal Officer	Direct	Sale	11,132	12.34	$137,368.88	87,568	4
2025-10-02	Heier, Jeffrey S.	Officer	Chief Scientific Officer	Direct	Sale	10,502	11.04	$115,942.08	249,409	4
2025-10-02	Kaiser, Peter	Officer	Chief Development Officer	Direct	Sale	9,653	11.03	$106,472.59	194,440	4
2025-09-02	Notman, Donald	Officer	See Remarks	Direct	Sale	1,066	12.43	$13,250.38	308,807	4
2025-08-25	Heier, Jeffrey S.	Officer	Chief Scientific Officer	Direct	Sale	3,063	12.04	$36,878.52	259,911	4
2025-08-25	Kaiser, Peter	Officer	Chief Development Officer	Direct	Sale	3,011	12.04	$36,252.44	204,093	4
2025-08-25	Nayak, Sanjay	Officer	Chief Strategy Officer	Direct	Sale	1,885	12.04	$22,695.40	279,738	4
2025-08-25	Dugel, Pravin	Director,Officer	See Remarks	Direct	Sale	21,494	12.04	$258,787.76	3,227,244	4
2025-06-02	Waheed, Nadia	Officer	Chief Medical Officer	Direct	Sale	13,861	8.05	$111,581.05	206,805	4
2025-05-23	Kaiser, Peter	Officer	Chief Development Officer	Direct	Sale	2,974	7.17	$21,323.58	207,104	4
2025-05-23	Heier, Jeffrey S.	Officer	Chief Scientific Officer	Direct	Sale	3,024	7.18	$21,712.32	262,974	4
2025-05-23	Nayak, Sanjay	Officer	Chief Strategy Officer	Direct	Sale	1,862	7.17	$13,350.54	281,623	4
2025-05-23	Dugel, Pravin	Director,Officer	See Remarks	Direct	Sale	21,219	7.18	$152,352.42	3,499,099	4
2025-05-08	Lindstrom, Richard L Md	Director	-	Direct	Purchase	10,000	6.96	$69,600.00	172,704	4
2025-02-24	Nayak, Sanjay	Officer	Chief Strategy Officer	Direct	Sale	1,895	6.84	$12,961.80	283,485	4
2025-02-24	Dugel, Pravin	Director,Officer	See Remarks	Direct	Sale	21,475	6.87	$147,533.25	3,520,318	4
2025-02-24	Kaiser, Peter	Officer	Chief Development Officer	Direct	Sale	3,009	6.87	$20,671.83	210,078	4
2025-02-24	Heier, Jeffrey S.	Officer	Chief Scientific Officer	Direct	Sale	3,061	6.87	$21,029.07	265,998	4
2025-02-04	Notman, Donald	Officer	See Remarks	Direct	Sale	11,119	7.81	$86,839.39	193,444	4
2024-11-25	Kaiser, Peter	Officer	Chief Development Officer	Direct	Sale	2,897	9.01	$26,101.97	213,087	4
2024-11-25	Heier, Jeffrey S.	Officer	Chief Scientific Officer	Direct	Sale	2,948	9.01	$26,561.48	269,059	4
2024-11-25	Nayak, Sanjay	Officer	Chief Strategy Officer	Direct	Sale	1,814	9.00	$16,326.00	174,380	4
2024-11-25	Dugel, Pravin	Director,Officer	See Remarks	Direct	Sale	20,680	9.01	$186,326.80	791,793	4
2024-08-23	Dugel, Pravin	Director,Officer	See Remarks	Direct	Sale	20,880	9.02	$188,337.60	812,473	4
2024-08-23	Nayak, Sanjay	Officer	Chief Strategy Officer	Direct	Sale	1,832	9.02	$16,524.64	176,194	4
2024-05-23	Nayak, Sanjay	Officer	Chief Strategy Officer	Direct	Sale	2,274	5.84	$13,280.16	178,026	4
2024-05-23	Dugel, Pravin	Director,Officer	See Remarks	Direct	Sale	21,626	5.79	$125,214.54	833,353	4
2024-02-26	Summer, Road Llc	TenPercentOwner	-	Indirect	Purchase	930,851	7.52	$6,999,999.52	8,591,401	4
2024-02-05	Ozden, Rabia Gurses	Officer	Chief Medical Officer	Direct	Sale	6,346	4.86	$30,841.56	153,054	4
2024-02-05	Strassburger, Philip C.	Officer	General Counsel	Direct	Sale	6,029	4.86	$29,300.94	161,493	4
2024-02-05	Notman, Donald	Officer	Chief Financial Officer	Direct	Sale	6,212	4.86	$30,190.32	195,356	4
2024-02-05	Mattessich, Antony C.	Director,Officer	President and CEO	Direct	Sale	19,642	4.86	$95,460.12	588,701	4
2024-02-05	White, Christopher G	Officer	Chief Business Officer	Direct	Sale	5,910	4.86	$28,722.60	123,689	4
2024-01-31	White, Christopher G	Officer	Chief Business Officer	Direct	Sale	5,147	4.95	$25,477.65	89,619	4
2024-01-31	Ozden, Rabia Gurses	Officer	Chief Medical Officer	Direct	Sale	7,764	4.95	$38,431.80	92,767	4
2024-01-31	Mattessich, Antony C.	Director,Officer	President and CEO	Direct	Sale	18,338	4.95	$90,773.10	427,943	4
2024-01-31	Strassburger, Philip C.	Officer	General Counsel	Direct	Sale	6,831	4.95	$33,813.45	109,218	4
2024-01-31	Notman, Donald	Officer	Chief Financial Officer	Direct	Sale	6,433	4.95	$31,843.35	139,932	4
2023-12-14	Summer, Road Llc	TenPercentOwner	-	Indirect	Purchase	1,538,461	3.25	$4,999,998.25	7,660,550	4
2023-08-30	Mattessich, Antony C.	Director,Officer	President and CEO	Indirect	Purchase	6,500	3.81	$24,765.00	6,500	4
2023-07-07	Ozden, Rabia Gurses	Officer	Chief Medical Officer	Direct	Sale	832	4.93	$4,101.76	100,531	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

88.46%

Inst. Shares: 198,231,265

Shares Outstanding: 224,099,410

2025-12-31

101.18%

Inst. Shares: 189,452,389

Shares Outstanding: 187,241,483

2025-09-30

101.82%

Inst. Shares: 187,258,029

Shares Outstanding: 183,919,808

2025-06-30

90.38%

Inst. Shares: 155,991,093

Shares Outstanding: 172,594,662

2025-03-31

78.91%

Inst. Shares: 133,669,528

Shares Outstanding: 169,396,989

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	198,231,265	224,099,410	88.46%
2025-12-31	189,452,389	187,241,483	101.18%
2025-09-30	187,258,029	183,919,808	101.82%
2025-06-30	155,991,093	172,594,662	90.38%
2025-03-31	133,669,528	169,396,989	78.91%
2024-12-31	132,423,027	158,265,162	83.67%
2024-09-30	138,031,288	166,992,735	82.66%
2024-06-30	135,382,869	165,824,778	81.64%
2024-03-31	107,425,534	132,021,945	81.37%
2023-12-31	64,905,704	79,827,362	81.31%
2023-09-30	33,179,576	79,373,272	41.80%
2023-06-30	36,185,691	78,047,705	46.36%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

OCULAR THERAPEUTIX, INC (OCUL) — SEC Financial Statements & Analysis

OCULAR THERAPEUTIX, INC (OCUL) is a pharmaceutical preparations company, incorporated in DE. OCULAR THERAPEUTIX, INC trades on Nasdaq as: OCUL. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), OCULAR THERAPEUTIX, INC reported a -8.14% year-over-year revenue growth, a Gross Profit Margin of 87.11% (TTM), a Debt-to-Equity ratio of 0.29x, a Price-to-Sales (P/S) ratio of 42.44x (TTM), a Price-to-Book (P/B) ratio of 4.25x (TTM), at a market cap of $2.21B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -8.14%
Gross Profit Margin TTM: 87.11%
Debt To Equity: 0.29x
P/S TTM: 42.44x
P/B TTM: 4.25x
Market Cap: $2.21B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is OCULAR THERAPEUTIX, INC in?

OCULAR THERAPEUTIX, INC (OCUL) operates in the Pharmaceutical Preparations industry.

What is OCUL's market cap?

OCULAR THERAPEUTIX, INC (OCUL) has a market capitalization of $2.21B as of 2026-06-30.

What exchange does OCUL trade on?

OCULAR THERAPEUTIX, INC (OCUL) trades on the Nasdaq.

Where is OCULAR THERAPEUTIX, INC incorporated?

OCULAR THERAPEUTIX, INC is incorporated in DE.